← Human Trials & Peer-Reviewed Studies
Effects of gonadotropin-releasing hormone antagonist (GnRH-ant) cessation on trigger day in a GnRH-ant protocol: a meta-analysis.
Plain-language guide to PMID 39731472 (2025): meta-analysis of Gonadorelin.
Key Facts
- PMID
- 39731472
- Journal
- Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
- Year
- 2025
- Study type
- Meta-Analysis
- Authors
- Li X et al. (6 authors)
- DOI
- 10.1080/01443615.2024.2444496
What This Paper Covers, in Plain Language
What It Covers
Researchers studied Gonadorelin in this meta-analysis publication.
This study aimed to systematically evaluate the effects of GnRH-ant cessation on trigger day on in vitro fertilisation outcomes following the GnRH-ant protocol.
Who the Included Studies Covered
PubMed tags the participants as women only.
The eligible studies included at least one of the main outcomes: number of oocytes retrieved, proportion of mature oocytes, implantation rate or clinical pregnancy rate.
How the Review Was Done
The researchers searched PubMed, Ovid/MEDLINE, Wanfang, VIP, CNKI and ClinicalTrials.gov databases.
The last search was conducted on 10 December 2023 in English or Chinese, without time limitations on the collection of studies from the databases.
The references in these articles were manually searched.
Randomised controlled trials (RCTs) and cohort studies aimed at assessing the effects of GnRH-ant cessation on trigger day using the GnRH-ant protocol were included.
What Was Measured
This study aimed to systematically evaluate the effects of GnRH-ant cessation on trigger day on in vitro fertilisation outcomes following the GnRH-ant protocol.
The subject headings attached to it are Fertilization in Vitro, Gonadotropin-Releasing Hormone, Hormone Antagonists, Oocyte Retrieval, Ovulation Induction and Pregnancy Rate.
Author keywords: GnRH antagonist, clinical outcomes, embryological outcomes, oocyte maturation, ovarian stimulation and trigger day.
What This Means in Plain Language
This is a meta-analysis of Gonadorelin.
Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2025 (Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology), a journal based in England.
More context: the Gonadorelin compound page, all human trials.
Our Notes on the Compound
Gonadorelin: A synthetic version of gonadotropin-releasing hormone (GnRH), the signal that tells the pituitary to release LH and FSH.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.